EP PI Survey_Att A-1_RFA Eval Language

Attachment A-1. Process Evaluation of the NIH Roadmap Epigenomics Program (NIDA)

Roadmap Epigenomics Program RFA Requirements for Evaluation

RFA Title and Number	RFA Requirement for Evaluation
	RFA Location	RFA Referenced Text
Epigenomics Data Analysis and Coordination Center – EDACC (U01) RFA-RM-07-014	Part II, Section I.1 Evaluation	As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the EDACC, as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.”
	Section VI.3 Reporting	Periodically, throughout the life of the program, awardees may be required to provide data that can be used to evaluate program progress, such as (but not limited to) the following: Completion of reference epigenome maps Submission of REMCs/EDACCs products to a public database Examples of how new technologies (e.g., methods, software) are used Examples of innovations Collaboration with other Roadmap Epigenomics Program participants (REMCs, NCBI, Technology RFA awardees, demonstration project RFA awardees) Multi-REMC/EDACC authored publications Communication of EDACC methods and results in a variety of settings Adoption of cutting edge methods, algorithms Such information may be used in evaluations of the EDACC as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program.
Reference Epigenome Mapping Centers (U01) RFA-RM-07-013	Part II, Section I.1 Evaluation	As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the REMCs as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.”
	IV.6. Other Submission Requirements	Applicants must plan to submit progress reports twice per year-once at the time of the non-competing continuation and once at a time to be determined by program staff. Program staff will use information from reports, site visits, etc. to evaluate each grantees progress and the success of the overall program; this information will be used to determine if funding levels should be increased or decreased for future years, for each grant and for the program. Progress will also be evaluated with the assistance of external advisors at the biannual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below).
Technology Development in Epigenetics (R01) RFA-RM-07-011	Part II, Section I.1 Evaluation	As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the Technology Development projects, as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.”
	IV.6. Other Submission Requirements	This initiative is part of a broader program in Epigenomics funded as part of the NIH Roadmap. In order to fulfill requirements for oversight of the Epigenomics Program as a whole, NIH staff may have to present status reports on individual initiatives to coincide with NIH Office of the Director timeframes. Thus, in addition to the annual progress report required at the time of submission of the noncompeting continuation application, awardees may be required to submit additional progress updates at a time to be determined by NIH. Program staff will use information from reports, site visits, etc. to evaluate each grantee’s progress and the success of the overall program. Progress will also be evaluated with the assistance of external advisors at the annual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below).
Technology Development in Epigenetics (R21) RFA-RM-07-012	Part II, Section I.1 Evaluation	As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the Technology Development projects, as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.”
	IV.6. Other Submission Requirements	This initiative is part of a broader program in Epigenomics funded as part of the NIH Roadmap. In order to fulfill requirements for oversight of the Epigenomics Program as a whole, NIH staff may have to present status reports on individual initiatives to coincide with NIH Office of the Director timeframes. Thus, in addition to the annual progress report required at the time of submission of the noncompeting continuation application, awardees may be required to submit additional progress updates at a time to be determined by NIH. Program staff will use information from reports, site visits, etc. to evaluate each grantee’s progress and the success of the overall program. Progress will also be evaluated with the assistance of external advisors at the annual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below).
Epigenomics of Human Health and Disease (R01) RFA-RM-08-017	Part II. Section I.1. Evaluation	As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the initiative as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program mid-course evaluation will be directed by the Roadmap Epigenomics Working Group. Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.”
	Section IV.6 Other Submission Requirements	This initiative is part of a broader program in Epigenomics funded as part of the NIH Roadmap. In order to fulfill requirements for oversight of the Roadmap Epigenomics Program as a whole, NIH staff may need to present status reports on individual initiatives to coincide with NIH Office of the Director timeframes. Thus, in addition to the annual Non-Competing Grant Process Report (PHS 2590, http://grants.nih.gov/grants/funding/2590/2590.htm), awardees may be required to submit additional progress updates at a time to be determined by NIH. Program staff will use information from reports, site visits, etc. to evaluate each grantee’s progress and the success of the overall program. Progress will also be evaluated with the assistance of external advisors at the annual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below).
Discovery of Novel Epigenetic Marks in Mammalian Cells (R01) RFA-RM-07-015	Part II, Section I.1 Evaluation	As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the Epigenetic Mark Discovery projects, as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.”
	Section IV.6 Other Submission Requirements	This initiative is part of a broader program in Epigenomics funded as part of the NIH Roadmap. In order to fulfill requirements for oversight of the Epigenomics Program as a whole, NIH staff may have to present status reports on individual initiatives to coincide with NIH Office of the Director timeframes. Thus, in addition to the annual progress report required at the time of submission of the noncompeting continuation application, awardees may be required to submit additional progress updates at a time to be determined by NIH. Program staff will use information from reports, site visits, etc. to evaluate each grantee’s progress and the success of the overall program. Progress will also be evaluated with the assistance of external advisors at the annual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below).
Discovery of Novel Epigenetic Marks in Mammalian Cells (R21) RFA-RM-07-016	Part II, Section I.1 Evaluation	As part of good program management, NIH assesses the implementation and effectiveness of its programs using evaluation tools and techniques. Grantees may be asked to provide information for program evaluation purposes, both locally and at the national level. Such information may be used in evaluations of the Epigenetic Mark Discovery projects, as well as the “Mid-Course” review of the entire Roadmap Epigenomics Program. Note that the Roadmap Epigenomics Program Mid-Course evaluation will be directed by the Epigenomics Working Group (EWG). Applicants are advised to review the additional details on evaluation that are provided in Section IV.6. Application and Submission Information, “Other Submission Requirements.”
	Section IV.6 Other Submission Requirements	This initiative is part of a broader program in Epigenomics funded as part of the NIH Roadmap. In order to fulfill requirements for oversight of the Epigenomics Program as a whole, NIH staff may have to present status reports on individual initiatives to coincide with NIH Office of the Director timeframes. Thus, in addition to the annual progress report required at the time of submission of the noncompeting continuation application, awardees may be required to submit additional progress updates at a time to be determined by NIH. Program staff will use information from reports, site visits, etc. to evaluate each grantee’s progress and the success of the overall program. Progress will also be evaluated with the assistance of external advisors at the annual meeting and at the mid-course review of the entire Roadmap Epigenomics Program (see “Management and Evaluation” below).